Trifluoromethanesulfonic Acid

Trifluoromethanesulfonic Acid

SCHEMBL542504

O=C1CCC(=O)N1I.O=S(=O)(O)C(F)(F)F

nearest known ligand 0.30

Full drug profile on Sugi Atlas →

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoromethanesulfonic Acid SCHEMBL16612173 0.81 GPR3 (0.32)
Trifluoromethanesulfonic Acid SCHEMBL8011536 0.81 GPR3 (0.32)
Trifluoromethanesulfonic Acid SCHEMBL64813 0.80 ALDH1A1 (0.31) ALDH1A1L3MBTL1
Trifluoroacetic Acid SCHEMBL2053629 0.76 CA12 (0.31) ALDH1A1
SCHEMBL1058967 0.75
SCHEMBL18779 0.75
Hydrogen Sulfide SCHEMBL15467095 0.72
SCHEMBL30271302 0.72
Iodide SCHEMBL2789427 0.72
Trifluoromethanesulfonic Acid SCHEMBL31124997 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106317130-B The batch synthesis method of table lactose 中国农业大学 2019-02-05 CN claimed
US-20060166278-A1 Method for synthesizing sugar chain(s) MITSUBISHI CHEMICAL CORPORATION (JP) 2006-07-27 US claimed
EP-1640379-A1 METHOD OF SYNTHESIZING SUGAR CHAIN Mitsubishi Chemical Corporation (JP) 2006-03-29 EP claimed
CN-1293200-A Process for preparing saponin library by one-step or two-step random reaction SHANGHAI INST ORGANIC CHEM (CN) 2001-05-02 CN claimed
CN-1293199-A Saponin library of rhammose-substituted beta-o-gluco-diosgenin and its preparing process and application SHANGHAI INST ORGANIC CHEM (CN) 2001-05-02 CN claimed
US-11332490-B1 Compounds and methods for treating osteoarthritis ACADEMIA SINICA (TW) 2022-05-17 US disclosed
CN-106317130-B The batch synthesis method of table lactose 中国农业大学 2019-02-05 CN disclosed
EP-2857411-B1 METHOD FOR PREPARING FULLY PROTECTION HEPARIN PENTASACCHARIDE AND INTERMEDIATE THEREOF ZHEJIANG HISUN PHARM CO LTD (CN) 2017-12-06 EP disclosed
EP-2415775-B1 AGENT FOR INHIBITING THICKENING OF PERITONEAL MEMBRANE CCI CORP (JP) 2017-08-23 EP disclosed
US-9310366-B2 Anthrax carbohydrates, synthesis and uses thereof UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2016-04-12 US disclosed
US-9250238-B2 Pathogen detection PURDUE RESEARCH FOUNDATION (US) 2016-02-02 US disclosed
US-20150284419-A1 METHOD FOR PREPARING FULLY PROTECTION HEPARIN PENTASACCHARIDE AND INTERMEDIATE THEREOF ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) 2015-10-08 US disclosed
US-5908833-A GLUCOCORTICOSTEROID CHEMICALLY BOUND TO A SUGAR AKTIEBOLAGET ASTRA (SE) 1999-06-01 US disclosed
EP-0912613-A1 SYNTHETIC POLYSACCHARIDES, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SANOFI (FR) 1999-05-06 EP disclosed
US-5773596-A Preparation of ganglioside having ceramide moiety labeled with fluorescence DAIKIN INDUSTRIES, LTD. (JP) 1998-06-30 US disclosed
WO-1998003554-A1 SYNTHETIC POLYSACCHARIDES, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SANOFI (FR) 1998-01-29 WO disclosed
EP-0765883-A1 GANGLIOSIDE HAVING FLUORESCENCE-LABELLED CERAMIDE PORTION AND PROCESS FOR PRODUCING THE SAME DAIKIN INDUSTRIES, LIMITED (JP) 1997-04-02 EP disclosed
CN-1114654-A Novel colon- or ileum-specific steroid derivatives ASTRA AB (SE) 1996-01-10 CN disclosed
EP-0678097-A1 NOVEL COLON- OR ILEUM-SPECIFIC STEROID DERIVATIVES AKTIEBOLAGET ASTRA (SE) 1995-10-25 EP disclosed
WO-1994015947-A1 NOVEL COLON- OR ILEUM-SPECIFIC STEROID DERIVATIVES ASTRA AKTIEBOLAG (SE) 1994-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150284419-A1 METHOD FOR PREPARING FULLY PROTECTION HEPARIN PENTASACCHARIDE AND INTERMEDIATE THEREOF HABP2, HPSE, PLG ALDH1A1 2108/4885L3MBTL1 3461/4885
US-11332490-B1 Compounds and methods for treating osteoarthritis SULT1E1, STS, ARSA ALDH1A1 288/4885L3MBTL1 1429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.